Bundesinstitut für Arzneimittel und Medizinprodukte

Bundesinstitut für Arzneimittel und Medizinprodukte
Name	Bundesinstitut für Arzneimittel und Medizinprodukte
Formed	1994
Headquarters	Bonn
Employees	~1,100

Contents

Bundesinstitut für Arzneimittel und Medizinprodukte is Germany's federal authority responsible for the assessment, approval and surveillance of pharmaceuticals and medical devices, interacting with European and international bodies such as European Medicines Agency, World Health Organization, Council of the European Union, Federal Ministry of Health (Germany), and European Commission. It performs regulatory, scientific and supervisory roles that connect institutions like Paul-Ehrlich-Institut, Robert Koch Institute, Deutsches Arzneimittelinstitut, Bundesinstitut für Risikobewertung, and agencies in countries such as France, United Kingdom, United States, and Japan. The institute's remit implicates legislation and policy instruments including the Medicinal Products Act (Germany), Good Manufacturing Practice, Clinical Trials Regulation (EU), European Pharmacopoeia, and international agreements such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Geschichte

The institute was created in 1994 amid reforms linked to debates involving Helmut Kohl, Klaus Kinkel, Bundesgesundheitsministerium, German reunification, Federal Republic of Germany, and earlier institutions like the Bundesgesundheitsamt and the Deutsche Arzneimittel-Kommission. Its institutional development was influenced by incidents and policy responses involving actors such as Thalidomide scandal, HIV blood scandal, Paul Ehrlich, and standards set by European Union directives and the World Health Organization, while administrative relocations connected it to cities including Bonn, Berlin, Bavaria, and federal cabinets under chancellors Gerhard Schröder and Angela Merkel.

The institute assesses marketing authorisation applications and post-market safety in coordination with bodies such as European Medicines Agency, Pharmacovigilance Risk Assessment Committee, Committee for Medicinal Products for Human Use, Paul-Ehrlich-Institut, and national ministries like the Federal Ministry of Health (Germany), implementing statutes such as the Medicinal Products Act (Germany), Medical Devices Regulation (EU), and Clinical Trials Regulation (EU). It issues scientific opinions used by courts such as the Bundesverwaltungsgericht and advisory groups including Bundesärztekammer, Kassenärztliche Bundesvereinigung, Robert Koch Institute, and international partners like World Health Organization and European Commission. The institute coordinates inspections, lab testing, and risk communication with stakeholders such as pharmaceutical industry, European Federation of Pharmaceutical Industries and Associations, non-governmental organizations including Transparency International, and patient groups such as Deutsche Stiftung Patientenschutz.

The institute's organisational chart comprises departments for authorisation, pharmacovigilance, clinical trials, medical devices, laboratory services, and central administration, interacting with entities such as European Medicines Agency, Paul-Ehrlich-Institut, Robert Koch Institute, Bundesinstitut für Risikobewertung, and regional authorities in North Rhine-Westphalia and Bonn. Leadership is appointed through processes involving the Federal Ministry of Health (Germany), parliamentary oversight by the Bundestag, and supervision linked to federal civil service law and comanagement with scientific advisory boards including representatives from Charité – Universitätsmedizin Berlin, Heidelberg University Hospital, University of Munich, and professional societies like Deutsche Gesellschaft für Kardiologie and German Society for Clinical Chemistry.

The institute evaluates marketing authorisations, variations, and periodic safety update reports for medicines in cooperation with committees such as the Committee for Medicinal Products for Human Use, Pharmacovigilance Risk Assessment Committee, and national agencies including Agence nationale de sécurité du médicament et des produits de santé and Medicines and Healthcare products Regulatory Agency, applying guidelines from the European Pharmacopoeia, Good Clinical Practice, and international standards like the ICH guidelines. For medical devices it enforces Medical Devices Regulation (EU), coordinates with Notified bodies, and participates in vigilance networks linking to European Commission, World Health Organization, and national hospitals such as Charité – Universitätsmedizin Berlin and Universitätsklinikum Heidelberg, while conducting market surveillance, inspections, and recalls in liaison with courts like the Bundesverwaltungsgericht and enforcement bodies including regional health authorities.

The institute undertakes regulatory science, pharmacoepidemiology, toxicology, and biomedical analytics in collaboration with universities and research centres such as Charité – Universitätsmedizin Berlin, Heidelberg University, Max Planck Society, Fraunhofer Society, Robert Koch Institute, Paul-Ehrlich-Institut, and international projects under European Commission research programmes and the Horizon Europe framework. Its laboratories and expert committees produce scientific opinions, risk assessments, and methodological work on topics referenced by journals and institutions including The Lancet, New England Journal of Medicine, European Journal of Clinical Pharmacology, World Health Organization, and professional societies such as the German Society for Clinical Pharmacology.

The institute has faced criticism and controversy in relation to risk communication, approval timelines, transparency, and conflict-of-interest questions raised by stakeholders including Transparency International, patient organisations like Deutsche Stiftung Patientenschutz, media outlets such as Der Spiegel, Süddeutsche Zeitung, and parliamentary inquiries in the Bundestag. Debates have referenced historical cases including the Thalidomide scandal, regulatory disputes with European Medicines Agency decisions, and public discussions involving politicians such as Karl Lauterbach and ministers from the Federal Ministry of Health (Germany), prompting reforms in procedures, stakeholder engagement, and cooperation with bodies such as Paul-Ehrlich-Institut and Robert Koch Institute.

Category:Government agencies of Germany Category:Medical and health organisations based in Germany